#treatmentoptions — Public Fediverse posts

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO, August 24, 2026–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European …
#Europe #EU #ACADIAPharmaceuticals #DAYBU #EuropeanCommission #EuropeanUnion #neurodevelopmentaldisorder #pediatricpatients #raredisease #Rettsyndrome #treatmentoption #treatmentoptions
https://www.europesays.com/europe/122619/

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNB…
#Europe #EU #adultpatients #breastcancer #EuropeanUnion #GileadSciences #metastaticbreastcancer #metastaticdisease #systemictherapy #treatmentoption #treatmentoptions #Trodelvy #unresectable
https://www.europesays.com/europe/122410/

European Commission grants orphan designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for Cushing’s syndrome of endogenous origin

The European Commission has gran…
#Europe #EU #ACTHlevels #adrenalgland #adrenocorticotropichormone #Cushing'sdisease #Cushing'ssyndrome #diseaseburden #endocrinedisorder #EuropeanCommission #EuropeanUnion #Lundbeck #monoclonalantibody #OrphanDesignation #pituitarytumor #treatmentoptions
https://www.europesays.com/europe/122278/

AstraZeneca Halts Key Lung-Cancer Trial–But Shares Barely Flinch

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), one of the world’s largest pharmaceutical companies with a major…
#EuropeSays #Britain #Europe #EU #AstraZeneca #failedtrial #salesopportunity #treatmentoptions
https://www.europesays.com/britain/107410/

https://www.europesays.com/britain/107410/ AstraZeneca Halts Key Lung-Cancer Trial–But Shares Barely Flinch #AstraZeneca #FailedTrial #SalesOpportunity #TreatmentOptions

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) …
#NewsBeep #News #Medication #Ecopipam #foodanddrugadministration #Health #JAMANeurology #NDA #OrphanDrugDesignation #pediatricpatients #teva-pharmaceuticals #TouretteSyndrome #treatmentoption #treatmentoptions #UK #UnitedKingdom
https://www.newsbeep.com/uk/743230/

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) is a …
#NewsBeep #News #Medication #AU #Australia #Ecopipam #foodanddrugadministration #Health #JAMANeurology #NDA #OrphanDrugDesignation #pediatricpatients #tevapharmaceuticals #tourettesyndrome #treatmentoption #treatmentoptions
https://www.newsbeep.com/au/861088/

AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant

AstraZeneca has halted its lung cancer treatment trial (Reuters) Pharmaceutical giant AstraZeneca has suffered a fresh setback after…
#EuropeSays #Britain #Europe #EU #AstraZeneca #Cancer #cervicalcancer #Lungcancer #SusanGalbraith #treatmentoptions
https://www.europesays.com/britain/105352/

https://www.europesays.com/britain/105352/ AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant #AstraZeneca #Cancer #CervicalCancer #LungCancer #SusanGalbraith #TreatmentOptions

Istanbul Care Announces Updated 2026 Hair Transplant Packages for International Patients Traveling to Turkey

Istanbul Care Clinic ISTANBUL, Turkey , Aug. 10, 2026 (GLOBE NEWSWIRE) — Istanbul Care today announced updated 2026…
#EuropeSays #Turkiye #Istanbul #hairtransplant #internationalpatients #packagestructure #treatmentcoordination #treatmentoptions #Turkey
https://www.europesays.com/turkiye/39093/

Istanbul Care Announces Updated 2026 Hair Transplant Packages for International Patients Traveling to Turkey

Istanbul Care Clinic ISTANBUL, Turkey , Aug. 10, 2026 (GLOBE NEWSWIRE) — Istanbul Care today announced updated 2026…
#EuropeSays #Turkiye #Istanbul #hairtransplant #internationalpatients #packagestructure #treatmentcoordination #treatmentoptions #Turkey
https://www.europesays.com/turkiye/37965/

https://www.europesays.com/ch/107672/ CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) #Archway #EuropeanMedicinesAgency #EuropeanUnion #EyeDiseases #EyeInjections #MacularDegeneration #MacularEdema #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #TreatmentOptions

https://www.europesays.com/ch/107616/ CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) #Archway #EuropeanMedicinesAgency #EuropeanUnion #EyeDiseases #EyeInjections #MacularDegeneration #MacularEdema #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #TreatmentOptions

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

Boehringer Ingelheim Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Not intended for UK an…
#Europe #EU #BoehringerIngelheim #Clinicaltrials #EuropeanCommission #EuropeanUnion #idiopathicpulmonaryfibrosis #immunomodulatoryeffects #lungfunction #PPF #progressivedisease #pulmonaryfibrosis #tolerabilityprofile #treatmentoptions
https://www.europesays.com/europe/97056/

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

Boehringer Ingelheim Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Not intended for UK an…
#Europe #EU #BoehringerIngelheim #Clinicaltrials #EuropeanCommission #EuropeanUnion #idiopathicpulmonaryfibrosis #immunomodulatoryeffects #lungfunction #PPF #progressivedisease #pulmonaryfibrosis #tolerabilityprofile #treatmentoptions
https://www.europesays.com/europe/96328/

WHO warns global cancer cases could nearly double by 2050

The World Health Organization (WHO) said on Wednesday that the number of new cancer cases diagnosed worldwide each…
#NewsBeep #News #Healthcare #cancer #cancerdetection #GautingLungClinic #Health #healthcare #treatmentoptions #UK #UnitedKingdom #wealthycountries #WorldHealthOrganization
https://www.newsbeep.com/uk/680796/

WHO warns global cancer cases could nearly double by 2050

The World Health Organization (WHO) said on Wednesday that the number of new cancer cases diagnosed worldwide each…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #cancer #cancerdetection #GautingLungClinic #Health #treatmentoptions #wealthycountries #WorldHealthOrganization
https://www.newsbeep.com/us/750939/

https://www.europesays.com/ie/575497/ WHO warns global cancer cases could nearly double by 2050 #cancer #CancerDetection #Éire #GautingLungClinic #Health #HealthCare #Healthcare #IE #Ireland #TreatmentOptions #WealthyCountries #WorldHealthOrganization

https://www.europesays.com/ch/97555/ Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) #EuropeanApproval #EuropeanCommission #EuropeanUnion #GeneReplacementTherapy #GeneTherapy #MotorFunction #MotorNeuron #Novartis #SpinalMuscularAtrophy #TreatmentOption #TreatmentOptions

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
#Europe #EU #EuropeanCommission #Europeanapproval #EuropeanUnion #genereplacementtherapy #genetherapy #motorfunction #motorneuron #Novartis #spinalmuscularatrophy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/86554/

https://www.europesays.com/ch/95770/ Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) #EuropeanApproval #EuropeanCommission #EuropeanUnion #GeneReplacementTherapy #GeneTherapy #MotorFunction #MotorNeuron #Novartis #SpinalMuscularAtrophy #TreatmentOption #TreatmentOptions

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
#Europe #EU #EuropeanCommission #Europeanapproval #EuropeanUnion #genereplacementtherapy #genetherapy #motorfunction #motorneuron #Novartis #spinalmuscularatrophy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/84390/

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced…
#Europe #EU #EuropeanCommission #ChemoCentryx #EuropeanMedicinesAgency #EuropeanUnion #FreseniusMedicalCare #granulomatosiswithpolyangiitis #marketingauthorisation #microscopicpolyangiitis #Patients #TAVNEOS #treatmentoptions
https://www.europesays.com/europe/81529/

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced…
#Europe #EU #ChemoCentryx #EuropeanCommission #EuropeanMedicinesAgency #EuropeanUnion #FreseniusMedicalCare #granulomatosiswithpolyangiitis #marketingauthorisation #microscopicpolyangiitis #Patients #TAVNEOS #treatmentoptions
https://www.europesays.com/europe/80568/

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced…
#Europe #EU #ChemoCentryx #European #EuropeanCommission #EuropeanMedicinesAgency #EuropeanUnion #FreseniusMedicalCare #granulomatosiswithpolyangiitis #marketingauthorisation #microscopicpolyangiitis #Patients #TAVNEOS #treatmentoptions
https://www.europesays.com/europe/80232/

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to…
#Europe #EU #EuropeanCommission #pediatricpatients #plaquepsoriasis #SKYRIZI #systemictherapy #treatmentoptions
https://www.europesays.com/europe/76750/

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Orion Oyj ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST         Orion Pharma’s ODM-212 Granted Orphan Designation for…
#Europe #EU #EuropeanCommission #CommitteeforOrphanMedicinalProducts #EuropeanMedicinesAgency #MalignantMesothelioma #ORIONCORPORATION #OrphanDesignation #treatmentoptions
https://www.europesays.com/europe/76724/

Sanofi (ENXTPA:SAN) Wins Japan Approval For Sarclisa Shot In Multiple Myeloma

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
#France #FR #Europe #EU #Sanofi #Japan #multiplemyeloma #regulatoryapproval #Sarclisa #treatmentoptions
https://www.europesays.com/france/38470/

Sanofi (ENXTPA:SAN) Wins Japan Approval For Sarclisa Shot In Multiple Myeloma

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
#EuropeSays #Japan #JP #multiplemyeloma #Nihon #regulatoryapproval #Sanofi #Sarclisa #treatmentoptions
https://www.europesays.com/japan/44069/

https://www.europesays.com/ch/82319/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #AdultPatients #CholinergicUrticaria #ChronicHives #ChronicSpontaneousUrticaria #ColdUrticaria #EAACI #Novartis #TreatmentOption #TreatmentOptions #urticaria

#CortisolDeficiency #LymeDisease #MoldExposure #HealthIssues #TreatmentOptions #WellnessJourney #RootCauseAnalysis #PersonalExperience #wellnesslife #wellnesshotel #wellbeingjourney #wellbeingwarrior #wellnes #wellbeingcoach #HealthDiscussion #Sporinox https://mastodon.social/@biohackingpathway/116607318295819162

Worst part about having once #LowBackPain:

It always looms around you, to hit you back when you worst expect it.

This time, same place, but the other side. Kudos to the fucking restaurant bathroom with their inclined seat.

#Health #LBP #LowBack #Back #Sitting #Sit #BackPain #Pain #TreatmentOptions #ChronicPain #BackPainRelief #Medical #Doctor #MedicalSchience #Spine #Traumatologist #Traumatology

Fuck, #LowBackPain comes again. To much time writing my #Laravel libraries I guess.

Any domestic treatments? I can barely stand up, not without screaming like a little girl.

#Health #Pain #LowBack #TreatmentOptions #ChronicPain #BackPainRelief